Enhancing the ability of macrophages to clear pathogens (Fig. 3A and B, Fig. S3), ALD-R491 could therefore be one of ALD-R491’s most distinct, significant, and unique therapeutic benefits in patients with COVID-19 as well as with post-COVID-19 syndromes. This evidence concerns the gene ABCD1 and COVID-19.